1
|
Segura L, Santos N, Flores R, Sikazwe D, McGibbon M, Blay V, Cheng KH. Exploring Tau Fibril-Disaggregating and Antioxidating Molecules Binding to Membrane-Bound Amyloid Oligomers Using Machine Learning-Enhanced Docking and Molecular Dynamics. Molecules 2024; 29:2818. [PMID: 38930883 PMCID: PMC11206291 DOI: 10.3390/molecules29122818] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2024] [Revised: 06/08/2024] [Accepted: 06/11/2024] [Indexed: 06/28/2024] Open
Abstract
Intracellular tau fibrils are sources of neurotoxicity and oxidative stress in Alzheimer's. Current drug discovery efforts have focused on molecules with tau fibril disaggregation and antioxidation functions. However, recent studies suggest that membrane-bound tau-containing oligomers (mTCOs), smaller and less ordered than tau fibrils, are neurotoxic in the early stage of Alzheimer's. Whether tau fibril-targeting molecules are effective against mTCOs is unknown. The binding of epigallocatechin-3-gallate (EGCG), CNS-11, and BHT-CNS-11 to in silico mTCOs and experimental tau fibrils was investigated using machine learning-enhanced docking and molecular dynamics simulations. EGCG and CNS-11 have tau fibril disaggregation functions, while the proposed BHT-CNS-11 has potential tau fibril disaggregation and antioxidation functions like EGCG. Our results suggest that the three molecules studied may also bind to mTCOs. The predicted binding probability of EGCG to mTCOs increases with the protein aggregate size. In contrast, the predicted probability of CNS-11 and BHT-CNS-11 binding to the dimeric mTCOs is higher than binding to the tetrameric mTCOs for the homo tau but not for the hetero tau-amylin oligomers. Our results also support the idea that anionic lipids may promote the binding of molecules to mTCOs. We conclude that tau fibril-disaggregating and antioxidating molecules may bind to mTCOs, and that mTCOs may also be useful targets for Alzheimer's drug design.
Collapse
Affiliation(s)
- Luthary Segura
- Neuroscience Department, Trinity University, San Antonio, TX 78212, USA;
| | - Natalia Santos
- Physics Department, Trinity University, San Antonio, TX 78212, USA;
| | - Rafael Flores
- Pharmaceutical Sciences Department, Feik School of Pharmacy, University of the Incarnate Word, San Antonio, TX 78209, USA; (R.F.); (D.S.)
| | - Donald Sikazwe
- Pharmaceutical Sciences Department, Feik School of Pharmacy, University of the Incarnate Word, San Antonio, TX 78209, USA; (R.F.); (D.S.)
| | - Miles McGibbon
- Institute of Quantitative Biology, Biochemistry and Biotechnology, University of Edinburgh, Edinburgh EH9 3BF, UK;
| | - Vincent Blay
- Department of Microbiology and Environmental Toxicology, University of California at Santa Cruz, Santa Cruz, CA 95064, USA;
| | - Kwan H. Cheng
- Neuroscience Department, Trinity University, San Antonio, TX 78212, USA;
- Physics Department, Trinity University, San Antonio, TX 78212, USA;
| |
Collapse
|
2
|
Gao X, Wang Z, Xiong L, Wu F, Gan X, Liu J, Huang X, Liu J, Tang L, Li Y, Huang J, Huang Y, Li W, Zeng H, Ban Y, Chen T, He S, Lin A, Han F, Guo X, Yu Q, Shu W, Zhang B, Zou R, Zhou Y, Chen Y, Tian H, Wei W, Zhang Z, Wei C, Wei Y, Liu H, Yao H, Chen Q, Zou Z. The bs-YHEDA peptide protects the brains of senile mice and thus recovers intelligence by reducing iron and free radicals. Free Radic Biol Med 2022; 190:216-225. [PMID: 35970250 DOI: 10.1016/j.freeradbiomed.2022.08.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/21/2022] [Revised: 08/08/2022] [Accepted: 08/08/2022] [Indexed: 11/24/2022]
Abstract
Iron accumulates in the brain with age and catalyzes free radical damage to neurons, thus playing a pathogenic role in Alzheimer's disease (AD). To decrease the incidence of AD, we synthesized the iron-affinitive peptide 5YHEDA to scavenge the excess iron in the senile brain. However, the blood-brain barrier (BBB) blocks the entrance of macromolecules into the brain, thus decreasing the therapeutic effects. To facilitate the entrance of the 5YHEDA peptide, we linked the low-density lipoprotein receptor (LDLR)-binding segment of ApoB-100 to 5YHEDA (named "bs-YHEDA"). The results of intravenous injections of bs-5YHEDA into senescent mice demonstrated that bs-YHEDA entered the brain, increased ferriportin levels, reduced iron and free radical levels, decreased the consequences of neuronal necrosis and ameliorated cognitive disfunction without kidney or liver damage. bs-5YHEDA is a safe iron and free radical remover that potentially alleviates aging and Alzheimer's disease.
Collapse
Affiliation(s)
- Xiaodie Gao
- Brain Hospital of Guangxi Zhuang Autonomous Region, Liuzhou, 542005, China; Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, 541199, China
| | - Zhigang Wang
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, 541199, China; Department of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, China
| | - Lijun Xiong
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, 541199, China
| | - Fengyao Wu
- Brain Hospital of Guangxi Zhuang Autonomous Region, Liuzhou, 542005, China; Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, 541199, China
| | - Xinying Gan
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, 541199, China
| | - Jinlian Liu
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, 541199, China
| | - Xiansheng Huang
- Brain Hospital of Guangxi Zhuang Autonomous Region, Liuzhou, 542005, China
| | - Juxia Liu
- Brain Hospital of Guangxi Zhuang Autonomous Region, Liuzhou, 542005, China
| | - Liling Tang
- Brain Hospital of Guangxi Zhuang Autonomous Region, Liuzhou, 542005, China
| | - Yanmei Li
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, 541199, China
| | - Jinli Huang
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, 541199, China
| | - Yuping Huang
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, 541199, China
| | - Wenyang Li
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, 541199, China
| | - Hongji Zeng
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, 541199, China
| | - Yunfei Ban
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, 541199, China
| | - Tingting Chen
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, 541199, China
| | - Suyuan He
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, 541199, China
| | - Anni Lin
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, 541199, China
| | - Fei Han
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, 541199, China
| | - Xuefeng Guo
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, 541199, China
| | - Qiming Yu
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, 541199, China
| | - Wei Shu
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, 541199, China
| | - Bo Zhang
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, 541199, China
| | - Ruyi Zou
- Chemical Department of Shangrao Normal University, Shangrao, 334001, China.
| | - Yong Zhou
- Central Hospital Affiliated to Taizhou University, Taizhou, 318000, China
| | - Yongfeng Chen
- Central Hospital Affiliated to Taizhou University, Taizhou, 318000, China
| | - Haibo Tian
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, 541199, China
| | - Wenjia Wei
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, 541199, China.
| | - Zhen Zhang
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, 541199, China
| | - Chuandong Wei
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, 541199, China
| | - Yuhua Wei
- Brain Hospital of Guangxi Zhuang Autonomous Region, Liuzhou, 542005, China
| | - Huihua Liu
- Brain Hospital of Guangxi Zhuang Autonomous Region, Liuzhou, 542005, China.
| | - Hua Yao
- Brain Hospital of Guangxi Zhuang Autonomous Region, Liuzhou, 542005, China.
| | - Qiang Chen
- Brain Hospital of Guangxi Zhuang Autonomous Region, Liuzhou, 542005, China.
| | - Zhenyou Zou
- Brain Hospital of Guangxi Zhuang Autonomous Region, Liuzhou, 542005, China; Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, 541199, China; Biochemistry Department of Purdue University, West Lafayette, IN47006, USA.
| |
Collapse
|
3
|
Exogenous Bioactive Peptides Have a Potential Therapeutic Role in Delaying Aging in Rodent Models. Int J Mol Sci 2022; 23:ijms23031421. [PMID: 35163342 PMCID: PMC8835817 DOI: 10.3390/ijms23031421] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Revised: 01/18/2022] [Accepted: 01/20/2022] [Indexed: 02/01/2023] Open
Abstract
In recent years, some exogenous bioactive peptides have been shown to have promising anti-aging effects. These exogenous peptides may have a mechanism similar to endogenous peptides, and some can even regulate the release of endogenous active peptides and play a synergistic role with endogenous active peptides. Most aging studies use rodents that are easy to maintain in the laboratory and have relatively homogenous genotypes. Moreover, many of the anti-aging studies using bioactive peptides in rodent models only focus on the activity of single endogenous or exogenous active peptides, while the regulatory effects of exogenous active peptides on endogenous active peptides remain largely under-investigated. Furthermore, the anti-aging activity studies only focus on the effects of these bioactive peptides in individual organs or systems. However, the pathological changes of one organ can usually lead to multi-organ complications. Some anti-aging bioactive peptides could be used for rescuing the multi-organ damage associated with aging. In this paper, we review recent reports on the anti-aging effects of bioactive peptides in rodents and summarize the mechanism of action for these peptides, as well as discuss the regulation of exogenous active peptides on endogenous active peptides.
Collapse
|
4
|
Xie Y, Wang Y, Jiang S, Xiang X, Wang J, Ning L. Novel strategies for the fight of Alzheimer's disease targeting amyloid-β protein. J Drug Target 2021; 30:259-268. [PMID: 34435898 DOI: 10.1080/1061186x.2021.1973482] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Alzheimer's disease (AD), which is recognised as a devastating neurodegenerative disease throughout the world and lack of effective treatments, is a growing concern in modern society with a growing population of elderly patients. A growing number of studies reveal that abnormal accumulation and deposition of Aβ is responsible for AD. Inspired by this, strategies for the treatment of AD targeting-Aβ clearance have been discussed for a long period, exploring new drugs which is capable of destroying soluble Aβ oligomers and unsolvable Aβ aggregates. In this paper, results of recent clinical trials on several anti-amyloid-β drugs are presented and several emerging anti-amyloid AD therapies based on recent studies are reviewed. Furthermore, some of the current challenges and novel strategies to prevent AD are addressed. Herein, this review focuses on current pharmacotherapy of AD targeting-Aβ and intends to design a promising therapeutic agent for AD treatment.
Collapse
Affiliation(s)
- Yang Xie
- Pharmaceutical Engineering Center, Chongqing Medical and Pharmaceutical College, Chongqing, China
| | - Yan Wang
- Chemistry and Chemical Engineering College, Huangshan University, Huangshan, China
| | - Shangfei Jiang
- Pharmaceutical Engineering Center, Chongqing Medical and Pharmaceutical College, Chongqing, China
| | - Xiaohong Xiang
- Pharmaceutical Engineering Center, Chongqing Medical and Pharmaceutical College, Chongqing, China
| | - Jianhua Wang
- Key Laboratory of Biorheological Science and Technology, Ministry of Education College of Bioengineering, Chongqing University, Chongqing, China
| | - Linhong Ning
- Pharmaceutical Engineering Center, Chongqing Medical and Pharmaceutical College, Chongqing, China
| |
Collapse
|
5
|
Yang W, Hao X, Zhang X, Zhang G, Li X, Liu L, Sun Y, Pan Y. Identification of antioxidant peptides from cheddar cheese made with Lactobacillus helveticus. Lebensm Wiss Technol 2021. [DOI: 10.1016/j.lwt.2021.110866] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
6
|
Chen Y, Luo X, Zou Z, Liang Y. The Role of Reactive Oxygen Species in Tumor Treatment and its Impact on Bone Marrow Hematopoiesis. Curr Drug Targets 2021; 21:477-498. [PMID: 31736443 DOI: 10.2174/1389450120666191021110208] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2019] [Revised: 09/21/2019] [Accepted: 10/08/2019] [Indexed: 02/08/2023]
Abstract
Reactive oxygen species (ROS), an important molecule inducing oxidative stress in organisms, play a key role in tumorigenesis, tumor progression and recurrence. Recent findings on ROS have shown that ROS can be used to treat cancer as they accelerate the death of tumor cells. At present, pro-oxidant drugs that are intended to increase ROS levels of the tumor cells have been widely used in the clinic. However, ROS are a double-edged sword in the treatment of tumors. High levels of ROS induce not only the death of tumor cells but also oxidative damage to normal cells, especially bone marrow hemopoietic cells, which leads to bone marrow suppression and (or) other side effects, weak efficacy of tumor treatment and even threatening patients' life. How to enhance the killing effect of ROS on tumor cells while avoiding oxidative damage to the normal cells has become an urgent issue. This study is a review of the latest progress in the role of ROS-mediated programmed death in tumor treatment and prevention and treatment of oxidative damage in bone marrow induced by ROS.
Collapse
Affiliation(s)
- Yongfeng Chen
- Taizhou University Hosipital, Taizhou University, Taizhou, 318000, Zhejiang, China.,Department of Basic Medical Sciences, Medical College of Taizhou University, Taizhou, 318000, Zhejiang, China
| | - Xingjing Luo
- Taizhou University Hosipital, Taizhou University, Taizhou, 318000, Zhejiang, China.,Department of Basic Medical Sciences, Medical College of Taizhou University, Taizhou, 318000, Zhejiang, China
| | - Zhenyou Zou
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, 541199, Guangxi, China
| | - Yong Liang
- Taizhou University Hosipital, Taizhou University, Taizhou, 318000, Zhejiang, China.,Department of Basic Medical Sciences, Medical College of Taizhou University, Taizhou, 318000, Zhejiang, China
| |
Collapse
|
7
|
Lei P, Ayton S, Bush AI. The essential elements of Alzheimer's disease. J Biol Chem 2020; 296:100105. [PMID: 33219130 PMCID: PMC7948403 DOI: 10.1074/jbc.rev120.008207] [Citation(s) in RCA: 127] [Impact Index Per Article: 31.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2020] [Revised: 11/19/2020] [Accepted: 11/20/2020] [Indexed: 02/05/2023] Open
Abstract
Treatments for Alzheimer’s disease (AD) directed against the prominent amyloid plaque neuropathology are yet to be proved effective despite many phase 3 clinical trials. There are several other neurochemical abnormalities that occur in the AD brain that warrant renewed emphasis as potential therapeutic targets for this disease. Among those are the elementomic signatures of iron, copper, zinc, and selenium. Here, we review these essential elements of AD for their broad potential to contribute to Alzheimer’s pathophysiology, and we also highlight more recent attempts to translate these findings into therapeutics. A reinspection of large bodies of discovery in the AD field, such as this, may inspire new thinking about pathogenesis and therapeutic targets.
Collapse
Affiliation(s)
- Peng Lei
- Department of Neurology and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, P.R. China; Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia.
| | - Scott Ayton
- Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia
| | - Ashley I Bush
- Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia.
| |
Collapse
|
8
|
Zou Z, Shao S, Zou R, Qi J, Chen L, Zhang H, Shen Q, Yang Y, Ma L, Guo R, Li H, Tian H, Li P, Yu M, Wang L, Kong W, Li C, Yu Z, Huang Y, Chen L, Shao Q, Gao X, Chen X, Zhang Z, Yan J, Shao X, Pan R, Xu L, Fang J, Zhao L, Huang Y, Li A, Zhang Y, Huang W, Tian K, Hu M, Xie L, Wu L, Wu Y, Luo Z, Xiao W, Ma S, Wang J, Huang K, He S, Yang F, Zhou S, Jia M, Zhang H, Lu H, Wang X, Tan J. Linking the low-density lipoprotein receptor-binding segment enables the therapeutic 5-YHEDA peptide to cross the blood-brain barrier and scavenge excess iron and radicals in the brain of senescent mice. ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS 2019; 5:717-731. [PMID: 31921964 PMCID: PMC6944740 DOI: 10.1016/j.trci.2019.07.013] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Introduction Iron accumulates in the brain during aging, which catalyzes radical formation, causing neuronal impairment, and is thus considered a pathogenic factor in Alzheimer's disease (AD). To scavenge excess iron-catalyzed radicals and thereby protect the brain and decrease the incidence of AD, we synthesized a soluble pro-iron 5-YHEDA peptide. However, the blood-brain barrier (BBB) blocks large drug molecules from entering the brain and thus strongly reduces their therapeutic effects. However, alternative receptor- or transporter-mediated approaches are possible. Methods A low-density lipoprotein receptor (LDLR)-binding segment of Apolipoprotein B-100 was linked to the 5-YHEDA peptide (bs-5-YHEDA) and intracardially injected into senescent (SN) mice that displayed symptoms of cognitive impairment similar to those of people with AD. Results We successfully delivered 5-YHEDA across the BBB into the brains of the SN mice via vascular epithelium LDLR-mediated endocytosis. The data showed that excess brain iron and radical-induced neuronal necrosis were reduced after the bs-5-YHEDA treatment, together with cognitive amelioration in the SN mouse, and that the senescence-associated ferritin and transferrin increase, anemia and inflammation reversed without kidney or liver injury. Discussion bs-5-YHEDA may be a mild and safe iron remover that can cross the BBB and enter the brain to relieve excessive iron- and radical-induced cognitive disorders.
Collapse
Affiliation(s)
- Zhenyou Zou
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, GX, China.,Medical School of Taizhou University, Taizhou, ZJ, China.,Biochemistry Department, Purdue University, West Lafayette, USA
| | - Shengxi Shao
- Division of Cell and Molecular Biology, Imperial College London, London, United Kingdom
| | - Ruyi Zou
- Chemistry Engineering Department, Shangrao Normal University, Shangrao, JX, China
| | - Jini Qi
- Medical School of Taizhou University, Taizhou, ZJ, China
| | - Liguan Chen
- Zhejiang Armed Police Corps, Hangzhou, ZJ, China
| | - Hui Zhang
- China Tobacco Gene Research Center, Zhengzhou Tobacco Research Institute of CNTC, Zhengzhou, HN, China
| | - Qiqiong Shen
- Medical School of Taizhou University, Taizhou, ZJ, China
| | - Yue Yang
- Clinical Laboratory Department, Wenzhou Medical University, ZJ, China
| | - Liman Ma
- Medical School of Taizhou University, Taizhou, ZJ, China
| | - Ruzeng Guo
- Medical School of Taizhou University, Taizhou, ZJ, China
| | - Hongwen Li
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, GX, China
| | - Haibo Tian
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, GX, China
| | - Pengxin Li
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, GX, China
| | - Mingfang Yu
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, GX, China
| | - Lu Wang
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, GX, China
| | - Wenjuan Kong
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, GX, China
| | - Caiyu Li
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, GX, China
| | - Zhenhai Yu
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, GX, China
| | - Yuping Huang
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, GX, China
| | - Li Chen
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, GX, China
| | - Qi Shao
- Medical School of Taizhou University, Taizhou, ZJ, China
| | - Xinyan Gao
- Medical School of Taizhou University, Taizhou, ZJ, China
| | - Xiaolin Chen
- Medical School of Taizhou University, Taizhou, ZJ, China
| | - Zhengbo Zhang
- Medical School of Taizhou University, Taizhou, ZJ, China
| | - Jianguo Yan
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, GX, China
| | - Xiaoyun Shao
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, GX, China
| | - Ru Pan
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, GX, China
| | - Lu Xu
- Clinical Laboratory of Jingyou Hospital, Xiaoshan, ZJ, China
| | - Jing Fang
- Medical School of Taizhou University, Taizhou, ZJ, China
| | - Lei Zhao
- Chemistry Engineering Department, Shangrao Normal University, Shangrao, JX, China
| | - Yaohui Huang
- Chemistry Engineering Department, Shangrao Normal University, Shangrao, JX, China
| | - Anqi Li
- Medical School of Taizhou University, Taizhou, ZJ, China
| | - Yuchong Zhang
- Medical School of Taizhou University, Taizhou, ZJ, China
| | - Wenkao Huang
- Medical School of Taizhou University, Taizhou, ZJ, China
| | - Kechun Tian
- Medical School of Taizhou University, Taizhou, ZJ, China
| | - Minxin Hu
- Medical School of Taizhou University, Taizhou, ZJ, China
| | - Linchao Xie
- Medical School of Taizhou University, Taizhou, ZJ, China
| | - Lingbin Wu
- Medical School of Taizhou University, Taizhou, ZJ, China
| | - Yu Wu
- Medical School of Taizhou University, Taizhou, ZJ, China
| | - Zhen Luo
- Medical School of Taizhou University, Taizhou, ZJ, China
| | - Wenxin Xiao
- Medical School of Taizhou University, Taizhou, ZJ, China
| | - Shanshan Ma
- Chemistry Engineering Department, Shangrao Normal University, Shangrao, JX, China
| | - Jianan Wang
- Chemistry Engineering Department, Shangrao Normal University, Shangrao, JX, China
| | - Kaixin Huang
- Chemistry Engineering Department, Shangrao Normal University, Shangrao, JX, China
| | - Siyuan He
- Chemistry Engineering Department, Shangrao Normal University, Shangrao, JX, China
| | - Fan Yang
- Chemistry Engineering Department, Shangrao Normal University, Shangrao, JX, China
| | - Shuni Zhou
- Medical School of Taizhou University, Taizhou, ZJ, China
| | - Mo Jia
- Medical School of Taizhou University, Taizhou, ZJ, China
| | - Hui Zhang
- Pathology Department, Affiliated Hospital of Taizhou University, ZJ, China
| | - Hongsheng Lu
- Pathology Department, Affiliated Hospital of Taizhou University, ZJ, China
| | - Xinjuan Wang
- Medical School of Taizhou University, Taizhou, ZJ, China
| | - Jie Tan
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, GX, China
| |
Collapse
|
9
|
Optimization and Identification of Antioxidant Peptide from Underutilized Dunaliella salina Protein: Extraction, In Vitro Gastrointestinal Digestion, and Fractionation. BIOMED RESEARCH INTERNATIONAL 2019; 2019:6424651. [PMID: 31531361 PMCID: PMC6720044 DOI: 10.1155/2019/6424651] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/22/2019] [Revised: 05/31/2019] [Accepted: 06/10/2019] [Indexed: 12/16/2022]
Abstract
DPPH• scavenging peptides (<3kDa) from underutilized Dunaliella salina protein were obtained by the following successive treatment, i.e., ultrasound extraction, simulated in vitro gastrointestinal digestion hydrolyzation, and membrane ultrafiltration classification. The optimal condition for ultrasound-assisted extraction was an ultrasound wave with 800 W of power treating a mixture of 60 mL of 1.0 mol L−1 NaOH and 2 g algae powder for 15 min. A high correlation (r=0.8146) between DPPH• scavenging activity and yield of the intact peptides showed their antioxidant capacity. Simulated in vitro digestion assay resulted in excellent DPPH• scavenging activity of the total peptide, amounting to (86.5 ± 10.1)%, comparing with the nondigestion samples at (46.8 ± 6.5)%. After fractionation, the 500-1000 Da fraction exhibited the highest DPPH• scavenging activity (81.2 ± 4.0)%, increasing 1.5 times due to digestion. Then, the 500-1000 Da fraction was analyzed by RPLC-Q Exactive HF mass spectrometer, and 4 novel peptides, i.e., Ile-Leu-Thr-Lys-Ala-Ala-Ile-Glu-Gly-Lys, Ile-Ile-Tyr-Phe-Gln-Gly-Lys, Asn-Asp-Pro-Ser-Thr-Val-Lys, and Thr-Val-Arg-Pro-Pro-Gln-Arg, were identified. From these amino acid sequences, hydrophobic residues accounted for 56%, which indicated their high antioxidant property. The results indicated that underutilized protein of Dunaliella salina could be a potential source of antioxidative peptides through simulated in vitro gastrointestinal digestion.
Collapse
|